Detailed Narrative
Q3 FY26 Performance Overview
Indoco Remedies reported consolidated net revenues of INR 4,343 million for Q3 FY26, marking a 7.9% YoY growth. Consolidated EBITDA to sales significantly improved to 7.3% (INR 315 million) compared to 3% (INR 120 million) in the same quarter last year. Standalone net revenues also grew by 6.8% YoY to INR 3,896 million, with a standalone EBITDA margin of 6.6% (INR 259 million).
Domestic Business & OTC Strategy
The domestic business experienced a slight decline, with revenues at INR 2,142 million, down 4.4% YoY, primarily due to challenges in acute therapies. However, the company's strategy focuses on shifting from acute to subchronic portfolios and targeting mass specialty doctors. In the OTC business, two new products, Sensodent DSP and Sensodent DPC, were launched, expanding the sensitivity and clean toothpaste segments. The Warren Remedies subsidiary, largely involved in OTC, grew by over 43% this quarter and 38% YTD.
International Business (Europe & US)
International Formulation business grew robustly by 26.2% YoY to INR 1,356 million. Europe sales increased by 36.9% YoY to INR 485 million, despite some approval delays that pushed manufacturing to the next quarter. The US business grew by 21.6% YoY to INR 341 million. Management aims for Europe revenues to grow 20% plus in the next few years, targeting INR 400-500 crores by FY28 or FY29.
API Business & Capacity Expansion
The API business recorded a 24% YoY growth, reaching INR 344 million. The Patalganga site, the largest for APIs, has seen capacity freed up as the Auric site (under Warren Remedies) started making KSMs and starting materials. This strategic move is expected to enable the Patalganga site to produce more finished API. The company anticipates API business to reach an annual run rate of INR 200 crores (including internal transfers) and external sales to ramp up from INR 25 crores to INR 40-45 crores next year.
Capital Allocation & Debt Management
The company's total gross debt stands at approximately INR 900 crores, with long-term debt around INR 590 crores. A repayment of INR 28 crores is scheduled for Q4 FY26, and annual repayments of INR 135-140 crores are planned for the next two years. Management projects consolidated debt to reduce from INR 920 crores to INR 775-800 crores by March 2027. No further significant capital expenditure is planned, with maintenance capex expected to be INR 35-40 crores per annum.
Regulatory Challenges and One-time Costs
Goa Plant II remains under a US FDA warning letter, though Goa Plant I (solid oral site) is unaffected, and new product launches are from this site. To mitigate supply challenges from Goa Plant II, the company has leased second-source supply. The quarter also saw INR 8-9 crores in one-time📎, non-recurring📎 costs related to remediation and penalties for unsupplied orders, which management expects not to repeat.